Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported two stock transfers used to repay personal loans. On August 15, he transferred 25,000 common shares at $2.00 per share in full satisfaction of a $50,000 personal loan. On August 14, he transferred 100,000 common shares at $2.00 per share to board member David Wickersham to fully repay a separate $200,000 personal loan made to him by Mr. Wickersham. Following these transactions, his reported direct holdings remained above 3.2 million common shares.
VSee Health, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,889,308 shares of Common Stock, representing 9.99% of the class as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which directly holds the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own those shares. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital. Signatures are dated 02/17/2026.
VSee Health, Inc. has called a virtual special meeting on March 2, 2026 to ask stockholders to approve a prior private placement under Nasdaq Listing Rule 5635(d). The company sold 9,836,065 shares of common stock (or pre-funded warrants) plus warrants for up to 19,672,130 shares in a November 2025 private offering, raising approximately $6 million at $0.61 per share.
Stockholders are being asked to approve the potential issuance of the warrant shares, which would exceed 20% of currently outstanding common stock, and to authorize possible adjournment of the meeting if more time is needed to gather votes. Common and Series A Preferred holders of record on February 2, 2026 are entitled to vote.
VSEE Health, Inc. received an amended Schedule 13G/A from a group led by Dominion Capital and Ascent Partners reporting reduced beneficial ownership of its common stock. The group now beneficially owns 1,014,654 shares, or about 2.97% of the company, based on 33,193,140 shares outstanding as of December 26, 2025.
The position includes 100,000 shares issued as closing shares under a March 20, 2025 promissory note and common stock purchase warrants exercisable for additional shares. The filers state this is an exit filing because they no longer own more than 5% and certify the holdings are not for control purposes.
VSee Health, Inc. is asking stockholders at a virtual special meeting on March 2, 2026 to approve a private placement-related share issuance and a possible meeting adjournment. The key item is approval, under Nasdaq Listing Rule 5635(d), of issuing common stock to holders of common stock purchase warrants from a prior private offering.
In that November 25, 2025 private offering, VSee agreed to sell 9,836,065 shares of common stock or pre-funded warrants and common warrants to purchase up to 19,672,130 shares for gross proceeds of approximately $6 million at $0.61 per share (or pre-funded warrant). The company notes that full warrant exercise would exceed 20% of its then-outstanding common stock, triggering the need for stockholder approval.
As of the February 2, 2026 record date, there were 36,776,205 shares of common stock outstanding and 1,788 shares of preferred stock entitled to 178,800 votes. The board unanimously recommends voting “FOR” both the private placement approval and the adjournment proposal.
VSee Health, Inc. director David L. Wickersham reported multiple stock awards of common shares on September 19, 2025. Each transaction is coded as an acquisition and represents shares issued under the company's 2024 Incentive Plan in line with its non-employee director compensation policy.
The footnotes explain that these grants compensate his board service for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with the number of shares for each period based on the closing stock price on the relevant date. One award shows 21,870 shares at $0.69 per share, and after that transaction he directly beneficially owned 282,397 common shares.
VSee Health director Scott Metzger reported multiple stock awards granted as director compensation. On September 19, 2025, he acquired several blocks of VSee Health common stock at prices ranging from $0.69 to $2.31 per share, including an award of 21,870 shares at $0.69 per share. After the largest reported award, he directly held 77,249 shares of common stock.
The footnotes state these shares were issued under VSee Health’s 2024 Incentive Plan in line with the company’s non‑employee director compensation policy, covering service as a director for quarters ended between June 30, 2024 and September 30, 2025. Each grant amount was based on the closing market price of the common stock on specified dates, turning Metzger’s quarterly board fees into equity ownership.
VSee Health director Kevin Lowdermilk reported several stock grants of common shares on September 19, 2025. Each transaction is coded as an acquisition and reflects shares issued under the company’s 2024 Incentive Plan in line with the non-employee director compensation policy.
The footnotes state these awards compensate his board service for quarters ended June 30 and September 30, 2024, December 31, 2024, and March 31, June 30, and September 30, 2025. Grant prices range from $0.69 to $2.31 per share, and after the latest award he directly beneficially owns 68,624 shares of VSee Health common stock.
VSee Health, Inc. (VSEE) director Colin P. O’Sullivan reported multiple stock awards of common stock as non-employee director compensation. On September 19, 2025, he acquired several blocks of common stock under the company’s 2024 Incentive Plan, with transaction code "A" indicating grants rather than open-market purchases or sales.
The reported awards include grants such as 21,870 shares at $0.69 per share and smaller blocks including 12,931 shares at $1.16, 12,500 shares at $1.20, 11,029 shares at $1.36, 10,067 shares at $1.49, and 227 shares at $2.31 per share. Footnotes state these shares were issued for O’Sullivan’s service as a director for quarters ended June 30, 2024 through September 30, 2025, based on the respective closing prices on specified dates.
VSee Health, Inc. director Cydonii V. Fairfax reported multiple stock awards of common shares on September 19, 2025. Each award is coded as an acquisition, reflecting stock granted under the company’s 2024 Incentive Plan as part of the non-employee director compensation policy.
The reported grants cover service as a director for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with grant-date prices ranging from $0.69 to $1.49 per share. After the most recent reported award of 21,870 shares at $0.69 per share, Fairfax directly holds 68,397 shares of VSee Health common stock.